ARTICLE | Clinical News
Telatinib: Phase I data
August 8, 2011 7:00 AM UTC
A dose-escalation, European Phase I trial in 39 patients with refractory colorectal cancer showed that twice-daily >=600 mg oral telatinib led to tumor shrinkage in 41% of patients, plus 22 cases of s...